Epiloid Biotechnologies

Pharmaceutical companies spend ~$0.8-1.6B on clinical trials for new neurology drugs, of which >90% fail, the drug never reaching market. The most cited factors in this failure is due to poor translation from preclinical models to human patients, whether due to lack of efficacy or unforeseen toxicity. Rodent models are the current gold standard of preclinical testing, as there is currently no useful preclinical human brain tissue model for measuring drug efficacy. To address this issue, advances in tissue engineering have resulted in a new platform for functional brain tissue testing: human stem cell derived cerebral organoids.